Alx Oncology Holdings IncALXO
Price$1.39

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$80.9MTTM through 30 Jun 2026
Free Cash Flow -$71MTTM through 30 Jun 2026

Margins

Current

Returns

-391.4%ROE
-172.2%ROA

Balance Sheet Health

Debt / Equity0.38x
Current Ratio2.07x
Net Debt-$48.3Mnet cash position
Cash & Equivalents$22.7M

Quality Metrics

Altman Z-Score-1.95
Piotroski F-Score3 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'18'19'20'21'22
FY2022: $0
Diluted EPS-$1.15TTM
'20'21'22'23'24'25
FY2025: $-1.90

Dividend

No dividend

Capital Allocation

R&D Spend$61.8M

Segment Performance

SegmentRevenueYoYOutlook
Immuno-Oncology Therapeutics$0
View details

Advancing Phase 2 ASPEN-09-Breast trial with topline data expected mid-2027, and Phase 1 ALX2004 trial with safety data expected in 2H 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.